Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Glycobond logo — The company’s first product is an assay for HCC diagnosis, H...

Glycobond

The company’s first product is an assay for HCC diagnosis, HepaCheC®

Founded 2011 Sweden Sweden 1 employees Grant Total: $50.00K Biotechnology, Health Care

General Information

Company Name Glycobond
Founded Year 2011
Location Sweden Sweden +1
Employees 1
Industries Biotechnology, Health Care
Funding Stage Grant
Social

Get notified when Glycobond moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Glycobond

Glycobond is a biotechnology startup based in Sweden that utilizes recombinant technology to produce carbohydrate-binding peptides for the diagnosis and monitoring of liver diseases and cancer. Their flagship product, HepaCheC®, is a CE-marked assay designed to aid in the diagnosis of primary liver cancer. Founded in 2011, the company operates within the Biotechnology and Health Care industries. In December 2017, Glycobond received a €50.00K grant investment from EASME - EU Executive Agency for SMEs. With a focus on addressing critical medical needs, Glycobond's innovative approach to diagnostics holds promise for the advancement of liver disease detection and treatment.

Taxonomy: medical diagnostics, cancer diagnosis, liver diseases, carbohydrate-binding peptides, recombinant technology, CE-marked assay, HCC diagnosis, liver cancer monitoring

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €50.00K 1 EASME - EU Executive Agency for SMEs 01 Dec 2017
Venture Round Unknown 1
LiU Invest
11 Apr 2017
Venture Round Unknown 1
Almi Invest
08 Apr 2015

Glycobond Alternatives & Competitors

Glycobond vs
Hunterdon Gastroenterology Associates
Hunterdon Gastroenterology Associates

Comprehensive care for liver disease and GI conditions, including advanced treatments for hemorrhoid...

Health Care
Glycobond vs
CBMC Cancer Center
CBMC Cancer Center

Comprehensive treatments for a wide spectrum of blood disorders and cancers.

Health Care
Glycobond vs
Diazyme Laboratories, Inc.
Diazyme Laboratories, Inc. United States

Innovations in Clinical Diagnostics

90 employees
Biotechnology, Health Care

FAQ About Glycobond

The company’s first product is an assay for HCC diagnosis, HepaCheC®
Glycobond was founded in 2011.
Glycobond is headquartered in Sweden.
Glycobond operates in the following industries: Biotechnology, Health Care.
Glycobond has approximately 1 employees.
Glycobond has completed 3 funding rounds, raising a total of $50.00K. The latest funding stage is Grant.
Top alternatives and competitors to Glycobond include Hunterdon Gastroenterology Associates, CBMC Cancer Center, Diazyme Laboratories, Inc., Base Therapeutics, Organo-ID. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Glycobond and Hunterdon Gastroenterology Associates are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Glycobond and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy